Table 3 Associations between treatment choice and participant characteristics.

	Pharmacotherapy type* N = 1,579‡		Behavioural support type† N = 1,717§
	Adj. OR (95%CI)	P	Adj. OR (95%CI)	P
Normal NMR (ref. slow)	0.96 (0.76–1.21)	0.74	0.67 (0.51–0.89)	0.005
Age	0.92 (0.82–1.03)	0.12	0.93 (0.81–1.07)	0.31
Female (ref. male)	0.83 (0.67–1.02)	0.07	0.94 (0.73–1.21)	0.64
Higher SES/ ABC1 (ref. C2DE)	1.53 (1.20–1.95)	0.001	1.10 (0.82–1.47)	0.53
White ethnicity (ref. other ethnicity)	5.14 (2.71–9.74)	<0.001	1.19 (0.57–2.49)	0.65
Higher dependence/HSI ≥ 4 (ref. HSI < 4)	1.10 (0.89–1.36)	0.36	1.27 (0.99–1.64)	0.07
Determination to quit
Very (ref. not determined)	0.89 (0.60–1.30)	0.53	0.63 (0.41–0.98)	0.04
Extremely (ref. not determined)	0.95 (0.65–1.40)	0.74	0.66 (0.43–1.02)	0.06
Last year quit attempt (ref. no attempt)	1.02 (0.82–1.25)	0.89	0.93 (0.72–1.20)	0.55
Poor physical health (ref. good physical health)	0.69 (0.55–0.86)	0.001	1.14 (0.87–1.48)	0.35
Poor wellbeing/WHO score ≤ 50% (ref. WHO score > 50%)	0.78 (0.63–0.97)	0.02	0.71 (0.55–0.92)	0.009
SSS Region
South (ref. North)	1.50 (1.09–2.07)	0.012	5.52 (3.50–8.71)	<0.001
Midlands (ref. North)	1.73 (1.38–2.16)	<0.001	15.6 (10.8–22.4)	<0.001

^*Varenicline/bupropion vs. nicotine replacement therapy (reference); ^†Group support vs. individual support (reference); ^‡Excludes cases with incomplete data (N = 103) and/or those with either NRT and varenicline/bupropion combination use (N = 86) or no pharmacotherapy use (N = 58); §Excludes cases with incomplete data (N = 103) and/or those with ‘other’ behavioural support (N = 6); Adj. OR = adjusted odds ratio (adjusted for all variables shown); CI = confidence interval; NMR = Nicotine metabolite ratio; HSI = Heaviness of Smoking Index; SES = socioeconomic status; SSS = Stop Smoking Services; ref. = reference category.

Search